M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: MAP2K1 Gene Mutation
Stage IVA Colorectal Cancer AJCC v7
KRAS Gene Mutation
Metastatic Colorectal Adenocarcinoma
Refractory Colorectal Adenocarcinoma
EGFR NP_005219.2:p.S492R
Stage IV Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Biological: Panitumumab
Drug: Trametinib

First Posted Date: 2017-03-22

Last Posted Date: 2025-01-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 59

Registration Number: NCT03087071

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Magnetic Resonance Whole Body Diffusion-Weighted Imaging in Finding Bone or Lymph Node Metastasis in Participants With High-Risk Prostate Cancer

Not Applicable

Active, not recruiting

Conditions: Prostate Carcinoma

Interventions: Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Magnetic Resonance Whole Body Diffusion-Weighted Imaging

First Posted Date: 2017-03-21

Last Posted Date: 2025-03-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 98

Registration Number: NCT03085043

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

Phase 2

Suspended

Conditions: Early-Stage Breast Carcinoma
Stage I Breast Cancer AJCC v7
Stage 0 Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Invasive Breast Carcinoma
Stage IB Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
Stage IIA Breast Cancer AJCC v6 and v7
Ductal Breast Carcinoma In Situ
Stage IA Breast Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Radiation: Partial Breast Irradiation
Other: Questionnaire Administration

First Posted Date: 2017-03-13

Last Posted Date: 2025-03-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 928

Registration Number: NCT03077841

Locations: 🇺🇸
MD Anderson West Houston, Houston, Texas, United States
🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States

and more 12 locations

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Phase 2

Active, not recruiting

Conditions: Appendix Adenocarcinoma
Human Papillomavirus-Related Anal Squamous Cell Carcinoma
Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
Human Papillomavirus-Related Squamous Cell Carcinoma of the Penis
Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma
Neuroendocrine Carcinoma
Pancreatic Neuroendocrine Tumor
Recurrent Merkel Cell Carcinoma
Recurrent Nasopharynx Carcinoma
Recurrent Peritoneal Malignant Mesothelioma

Interventions: Drug: Atezolizumab
Biological: Bevacizumab
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2017-03-08

Last Posted Date: 2025-04-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 133

Registration Number: NCT03074513

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Neoplasm in the Liver
Metastatic Uveal Melanoma

Interventions: Biological: Aldesleukin
Biological: Autologous CD8+ SLC45A2-specific T Lymphocytes
Drug: Cyclophosphamide
Biological: Ipilimumab

First Posted Date: 2017-03-03

Last Posted Date: 2024-01-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 34

Registration Number: NCT03068624

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 2

Terminated

Conditions: High Risk Myelodysplastic Syndrome
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions: Biological: Daratumumab

First Posted Date: 2017-03-01

Last Posted Date: 2023-09-21

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT03067571

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

Phase 2

Active, not recruiting

Conditions: EGFR Exon 20 Mutation
ERBB2 Gene Mutation
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions: Drug: Poziotinib

First Posted Date: 2017-02-28

Last Posted Date: 2025-05-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 93

Registration Number: NCT03066206

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

Phase 1

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
ERBB4 Gene Mutation
Refractory Malignant Solid Neoplasm
ERBB3 Gene Mutation
KRAS Gene Mutation
ERBB2 Gene Mutation
EGFR Gene Mutation
ERBB2 Gene Amplification
Metastatic Malignant Solid Neoplasm
EGFR Gene Amplification

Interventions: Drug: Everolimus
Drug: Neratinib
Drug: Palbociclib
Drug: Trametinib

First Posted Date: 2017-02-27

Last Posted Date: 2025-06-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 93

Registration Number: NCT03065387

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Afimoxifene in Reducing the Risk of Breast Cancer in Women With Mammographically Dense Breast

Phase 2

Completed

Conditions: Mammographically Dense Breast

Interventions: Other: Laboratory Biomarker Analysis
Drug: Afimoxifene
Other: Placebo
Other: Questionnaire Administration

First Posted Date: 2017-02-24

Last Posted Date: 2024-02-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 194

Registration Number: NCT03063619

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

Conditions: Diabetes
Pancreatic Cancer
Chronic Pancreatitis

Interventions: Other: Data Management and Monitoring

First Posted Date: 2017-02-23

Last Posted Date: 2019-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 25000

Registration Number: NCT03058926

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy